GlassScriptPhysician profile
Sarah E Peters
NPI 1710529961
$9,029.98
in general payments reported to CMS, 2019-2025
36 companies · $2,464 in 2025
The $2,464 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,013 · 2022: $845 · 2023: $1,858 · 2024: $2,850 · 2025: $2,464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,074 · Education: $98.34.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,073.89 |
| Education | $98.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,692.48 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,556.87 | 2021-2025 | Fasenra, Airsupra, Breztri |
| Regeneron Healthcare Solutions, INC. | $935.65 | 2021-2025 | Dupixent |
| Takeda Pharmaceuticals U.S.A., INC. | $832.31 | 2021-2025 | Cuvitru, Takhzyro, Hyqvia |
| Glaxosmithkline, LLC. | $716.34 | 2021-2025 | Nucala, Trelegy Ellipta |
| Csl Behring | $413.11 | 2023-2025 | Hizentra, Haegarda |
| Amgen INC. | $392.06 | 2022-2025 | Tezspire, Actimmune |
| Pharming Healthcare, INC. | $382.46 | 2021-2025 | Ruconest |
| Genentech USA, INC. | $261.64 | 2021-2025 | Xolair |
| Novartis Pharmaceuticals Corporation | $206.07 | 2021-2025 | |
| Optinose US, INC. | $171.46 | 2021-2025 | |
| Hospira, INC. | $155.49 | 2024-2025 | |
| Hikma Pharmaceuticals USA | $128.03 | 2023-2025 | Ryaltris |
| Incyte Corporation | $127.46 | 2021-2024 | Opzelura |
| Biocryst US Sales Co., LLC | $124.33 | 2021-2025 | Orladeyo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $114.24 | 2024-2025 | Adbry, Anzupgo |
| Kaleo, INC. | $107.74 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $72.66 | 2023-2024 | |
| Grifols USA, LLC | $66.63 | 2023-2025 | Prolastin-C Liquid |
| Teva Pharmaceuticals USA, INC. | $65.65 | 2021-2023 | Airduo Digihaler |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.25 | 2021 | |
| Mylan Specialty L.P. | $55.60 | 2024 | Yupelri |
| Merck Sharp & Dohme LLC | $54.38 | 2021-2025 | Vaxneuvance, Capvaxive |
| Octapharma USA, INC. | $51.38 | 2023-2024 | Octagam Immune Globulin (Human) |
| Lilly USA, LLC | $41.53 | 2025 | Ebglyss, Taltz |
| Organon LLC | $38.97 | 2025 | |
| Blueprint Medicines Corporation | $35.88 | 2024 | Ayvakit |
| Insmed, INC. | $29.18 | 2025 | Brinsupri, Arikayce |
| Dermavant Sciences, INC. | $28.91 | 2024 | Vtama |
| Aimmune Therapeutics, INC. | $21.47 | 2022 | |
| Cycle Pharmaceuticals INC | $18.32 | 2025 | Sajazir |
| Seqirus USA INC | $17.10 | 2025 | Flucelvax |
| Alk-Abello, INC | $16.01 | 2021 | |
| Ionis Pharmaceuticals, INC. | $15.37 | 2025 | Dawnzera |
| Jubilant Hollisterstier LLC | $13.00 | 2021 | |
| Horizon Therapeutics Plc | $12.95 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.